Organogenesis (ORGO) commends the decision by the U.S. Centers for Medicare & Medicaid Services on local coverage determination based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the Medicare population and is now set to become effective on February 12, 2025. Organogenesis offers 4 products for DFUs, including NuShield, and 2 for VLUs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORGO:
- Organogenesis Holdings Secures $130M Investment for Growth
- Organogenesis Reports Robust Third Quarter Growth
- Organogenesis reports Q3 EPS 9c, consensus (1c)
- Organogenesis sees FY24 revenue $455-$480M, consensus $456.15M
- Organogenesis announces $130M private placement offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
